Download PDF
Semin Liver Dis 2013; 33(02): 157-166
DOI: 10.1055/s-0033-1345719
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Does Antiviral Therapy for Chronic Hepatitis B Reduce the Risk of Hepatocellular Carcinoma?

Mahmoud Abu-Amara
1   Department of Hepatology, Toronto Western Hospital Liver Centre, McLaughlin Rotman Centre for Global Health, University of Toronto, Toronto, Canada
,
Jordan J. Feld
1   Department of Hepatology, Toronto Western Hospital Liver Centre, McLaughlin Rotman Centre for Global Health, University of Toronto, Toronto, Canada
› Author Affiliations
Further Information

Publication History

Publication Date:
08 June 2013 (online)

    Permissions and Reprints

Abstract

Chronic hepatitis B infection (CHB) is common and can lead to serious consequences including liver cirrhosis, failure, and hepatocellular carcinoma (HCC). The hepatitis B virus (HBV) has a simple genome, but a complex lifecycle that includes the production of covalently closed circular DNA (cccDNA). Currently approved antiviral treatments for CHB include interferon (IFN) and nucleos(t)ide analogues. These drugs work either by stimulating the immune system to eliminate virus-infected cells or to inhibit viral replication, respectively. The drugs do not affect the cccDNA pool in the nucleus; therefore, this molecule represents a persistent source of recurrent infection that is difficult to eradicate. With longer-term follow-up of patients treated with antiviral therapy, investigators have looked at whether treatment can prevent the development of HCC. Unfortunately, the data are fairly heterogeneous in terms of both quality and conclusions. IFN appears to reduce the risk of HCC, but the benefit seems to be restricted to cirrhotic patients who have a lasting response to therapy. Oral agents successfully suppress HBV DNA replication and slow or even reverse hepatic fibrosis. Studies suggest that long-term therapy reduces the risk of HCC in patients with active disease and again primarily in those with advanced fibrosis or cirrhosis. The mechanism by which any of the therapies reduce the risk of HCC is not clear. The authors review the lifecycle of HBV and mechanisms by which the virus may be carcinogenic followed by a review of the literature on the efficacy of therapy in reducing the risk of HCC.

Keywords

chronic hepatitis B infection - hepatocellular carcinoma - antivirals - interferon - nucleos(t)ide analogues
 

  • References

  • 1 Hepatitis B. Fact Sheet No. 204. Geneva, Switzerland: World Health Organization; 2012
    Google Scholar
  • 2 Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48 (2) 335-352
    CrossrefPubMedGoogle Scholar
  • 3 Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol 2008; 14 (27) 4300-4308
    CrossrefPubMedGoogle Scholar
  • 4 Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis 2010; 14 (1) 1-21 , vii
    CrossrefPubMedGoogle Scholar
  • 5 Kao JH, Chen PJ, Chen DS. Recent advances in the research of hepatitis B virus-related hepatocellular carcinoma: epidemiologic and molecular biological aspects. Adv Cancer Res 2010; 108: 21-72
    PubMedGoogle Scholar
  • 6 Lok AS. Prevention of hepatitis B virus-related hepatocellular carcinoma. Gastroenterology 2004; 127 (5) (Suppl. 01) S303-S309
    CrossrefPubMedGoogle Scholar
  • 7 Yang JD, Roberts LR. Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol 2010; 7 (8) 448-458
    CrossrefPubMedGoogle Scholar
  • 8 Zhang H, Zhai Y, Hu Z , et al. Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers. Nat Genet 2010; 42 (9) 755-758
    CrossrefPubMedGoogle Scholar
  • 9 Yeung P, Wong DK, Lai CL, Fung J, Seto WK, Yuen MF. Association of hepatitis B virus pre-S deletions with the development of hepatocellular carcinoma in chronic hepatitis B. J Infect Dis 2011; 203 (5) 646-654
    CrossrefPubMedGoogle Scholar
  • 10 Yuen MF, Tanaka Y, Shinkai N , et al. Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levels. Gut 2008; 57 (1) 98-102
    PubMedGoogle Scholar
  • 11 Sherman M, Bruix J, Porayko M, Tran T. AASLD Practice Guidelines Committee. Screening for hepatocellular carcinoma: the rationale for the American Association for the Study of Liver Diseases recommendations. Hepatology 2012; 56 (3) 793-796
    CrossrefPubMedGoogle Scholar
  • 12 El-Serag HB Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142 (6) 1264-1273.e1261
    CrossrefPubMedGoogle Scholar
  • 13 Kwon H, Lok AS. Hepatitis B therapy. Nat Rev Gastroenterol Hepatol 2011; 8 (5) 275-284
    PubMedGoogle Scholar
  • 14 Liaw YF, Sung JJ, Chow WC , et al; Cirrhosis Asian Lamivudine Multicentre Study Group. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351 (15) 1521-1531
    CrossrefPubMedGoogle Scholar
  • 15 Patient R, Hourioux C, Roingeard P. Morphogenesis of hepatitis B virus and its subviral envelope particles. Cell Microbiol 2009; 11 (11) 1561-1570
    CrossrefPubMedGoogle Scholar
  • 16 Shi YH, Shi CH. Molecular characteristics and stages of chronic hepatitis B virus infection. World J Gastroenterol 2009; 15 (25) 3099-3105
    CrossrefPubMedGoogle Scholar
  • 17 Beck J, Nassal M. Hepatitis B virus replication. World J Gastroenterol 2007; 13 (1) 48-64
    CrossrefPubMedGoogle Scholar
  • 18 Levrero M, Pollicino T, Petersen J, Belloni L, Raimondo G, Dandri M. Control of cccDNA function in hepatitis B virus infection. J Hepatol 2009; 51 (3) 581-592
    CrossrefPubMedGoogle Scholar
  • 19 Wei Y, Neuveut C, Tiollais P, Buendia MA. Molecular biology of the hepatitis B virus and role of the X gene. Pathol Biol (Paris) 2010; 58 (4) 267-272
    CrossrefPubMedGoogle Scholar
  • 20 Chan HL, Sung JJ. Hepatocellular carcinoma and hepatitis B virus. Semin Liver Dis 2006; 26 (2) 153-161
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Marcellin P, Gane E, Buti M, Afdhal N, Sievert W , et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013; 381 (9865) 468-475
    CrossrefPubMedGoogle Scholar
  • 22 Liu CJ, Chen BF, Chen PJ , et al. Role of hepatitis B virus precore/core promoter mutations and serum viral load on noncirrhotic hepatocellular carcinoma: a case-control study. J Infect Dis 2006; 194 (5) 594-599
    CrossrefPubMedGoogle Scholar
  • 23 Chemin I, Zoulim F. Hepatitis B virus induced hepatocellular carcinoma. Cancer Lett 2009; 286 (1) 52-59
    CrossrefPubMedGoogle Scholar
  • 24 Bonilla Guerrero R, Roberts LR. The role of hepatitis B virus integrations in the pathogenesis of human hepatocellular carcinoma. J Hepatol 2005; 42 (5) 760-777
    CrossrefPubMedGoogle Scholar
  • 25 Feitelson MA, Lee J. Hepatitis B virus integration, fragile sites, and hepatocarcinogenesis. Cancer Lett 2007; 252 (2) 157-170
    CrossrefPubMedGoogle Scholar
  • 26 Murakami Y, Saigo K, Takashima H , et al. Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocellular carcinomas. Gut 2005; 54 (8) 1162-1168
    CrossrefPubMedGoogle Scholar
  • 27 Bacon BR, Gordon SC, Lawitz E , et al; HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364 (13) 1207-1217
    CrossrefPubMedGoogle Scholar
  • 28 Kew MC. Hepatitis B virus x protein in the pathogenesis of hepatitis B virus-induced hepatocellular carcinoma. J Gastroenterol Hepatol 2011; 26 (Suppl. 01) 144-152
    CrossrefPubMedGoogle Scholar
  • 29 Sirma H, Giannini C, Poussin K, Paterlini P, Kremsdorf D, Bréchot C. Hepatitis B virus X mutants, present in hepatocellular carcinoma tissue abrogate both the antiproliferative and transactivation effects of HBx. Oncogene 1999; 18 (34) 4848-4859
    CrossrefPubMedGoogle Scholar
  • 30 Poussin K, Dienes H, Sirma H , et al. Expression of mutated hepatitis B virus X genes in human hepatocellular carcinomas. Int J Cancer 1999; 80 (4) 497-505
    CrossrefPubMedGoogle Scholar
  • 31 Hildt E, Munz B, Saher G, Reifenberg K, Hofschneider PH. The PreS2 activator MHBs(t) of hepatitis B virus activates c-raf-1/Erk2 signaling in transgenic mice. EMBO J 2002; 21 (4) 525-535
    CrossrefPubMedGoogle Scholar
  • 32 Hsieh YH, Su IJ, Wang HC , et al. Pre-S mutant surface antigens in chronic hepatitis B virus infection induce oxidative stress and DNA damage. Carcinogenesis 2004; 25 (10) 2023-2032
    CrossrefPubMedGoogle Scholar
  • 33 Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 2005; 5 (5) 375-386
    CrossrefPubMedGoogle Scholar
  • 34 Fensterl V, Sen GC. Interferons and viral infections. Biofactors 2009; 35 (1) 14-20
    CrossrefPubMedGoogle Scholar
  • 35 Fung J, Lai CL, Seto WK, Yuen MF. Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B. J Antimicrob Chemother 2011; 66 (12) 2715-2725
    CrossrefPubMedGoogle Scholar
  • 36 Neuveut C, Wei Y, Buendia MA. Mechanisms of HBV-related hepatocarcinogenesis. J Hepatol 2010; 52 (4) 594-604
    CrossrefPubMedGoogle Scholar
  • 37 Chang MH, You SL, Chen CJ , et al; Taiwan Hepatoma Study Group. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 2009; 101 (19) 1348-1355
    CrossrefPubMedGoogle Scholar
  • 38 Sung JJ, Tsoi KK, Wong VW, Li KC, Chan HL. Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2008; 28 (9) 1067-1077
    CrossrefPubMedGoogle Scholar
  • 39 Cammà C, Giunta M, Andreone P, Craxì A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 2001; 34 (4) 593-602
    CrossrefPubMedGoogle Scholar
  • 40 Yang YF, Zhao W, Zhong YD, Xia HM, Shen L, Zhang N. Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis. J Viral Hepat 2009; 16 (4) 265-271
    CrossrefPubMedGoogle Scholar
  • 41 Lai CL, Yuen MF. Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. Hepatology 2013; 57 (1) 399-408
    CrossrefPubMedGoogle Scholar
  • 42 Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999; 29 (3) 971-975
    CrossrefPubMedGoogle Scholar
  • 43 Lin SM, Tai DI, Chien RN, Sheen IS, Chu CM, Liaw YF. Comparison of long-term effects of lymphoblastoid interferon alpha and recombinant interferon alpha-2a therapy in patients with chronic hepatitis B. J Viral Hepat 2004; 11 (4) 349-357
    CrossrefPubMedGoogle Scholar
  • 44 Fattovich G, Giustina G, Realdi G, Corrocher R, Schalm SW. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 1997; 26 (5) 1338-1342
    CrossrefPubMedGoogle Scholar
  • 45 Krogsgaard K. The Long-Term Follow-up Investigator Group. The European Study Group on Viral Hepatitis (EUROHEP). Executive Team on Anti-Viral Treatment. The long-term effect of treatment with interferon-alpha 2a in chronic hepatitis B. J Viral Hepat 1998; 5 (6) 389-397
    CrossrefPubMedGoogle Scholar
  • 46 Ikeda K, Saitoh S, Suzuki Y , et al. Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: a pilot study. Cancer 1998; 82 (5) 827-835
    CrossrefPubMedGoogle Scholar
  • 47 Mazzella G, Saracco G, Festi D , et al. Long-term results with interferon therapy in chronic type B hepatitis: a prospective randomized trial. Am J Gastroenterol 1999; 94 (8) 2246-2250
    CrossrefPubMedGoogle Scholar
  • 48 Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 2001; 34 (2) 306-313
    CrossrefPubMedGoogle Scholar
  • 49 Truong BX, Seo Y, Kato M , et al. Long-term follow-up of Japanese patients with chronic hepatitis B treated with interferon-alpha. Int J Mol Med 2005; 16 (2) 279-284
    PubMedGoogle Scholar
  • 50 van Zonneveld M, Honkoop P, Hansen BE , et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 2004; 39 (3) 804-810
    CrossrefPubMedGoogle Scholar
  • 51 Yuen MF, Hui CK, Cheng CC, Wu CH, Lai YP, Lai CL. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology 2001; 34 (1) 139-145
    CrossrefPubMedGoogle Scholar
  • 52 Lin SM, Yu ML, Lee CM , et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 2007; 46 (1) 45-52
    CrossrefPubMedGoogle Scholar
  • 53 Tangkijvanich P, Thong-ngam D, Mahachai V, Kladchareon N, Suwangool P, Kullavanijaya P. Long-term effect of interferon therapy on incidence of cirrhosis and hepatocellular carcinoma in Thai patients with chronic hepatitis B. Southeast Asian J Trop Med Public Health 2001; 32 (3) 452-458
    PubMedGoogle Scholar
  • 54 Miyake Y, Kobashi H, Yamamoto K. Meta-analysis: the effect of interferon on development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Gastroenterol 2009; 44 (5) 470-475
    CrossrefPubMedGoogle Scholar
  • 55 Zhang CH, Xu GL, Jia WD, Li JS, Ma JL, Ge YS. Effects of interferon treatment on development and progression of hepatocellular carcinoma in patients with chronic virus infection: a meta-analysis of randomized controlled trials. Int J Cancer 2011; 129 (5) 1254-1264
    CrossrefPubMedGoogle Scholar
  • 56 Jin H, Pan N, Mou Y, Wang B, Liu P. Long-term effect of interferon treatment on the progression of chronic hepatitis B: Bayesian meta-analysis and meta-regression. Hepatol Res 2011; 41 (6) 512-523
    CrossrefPubMedGoogle Scholar
  • 57 Eun JR, Lee HJ, Kim TN, Lee KS. Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease. J Hepatol 2010; 53 (1) 118-125
    CrossrefPubMedGoogle Scholar
  • 58 Yuen MF, Seto WK, Chow DH , et al. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther 2007; 12 (8) 1295-1303
    PubMedGoogle Scholar
  • 59 Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol 2010; 53 (2) 348-356
    CrossrefPubMedGoogle Scholar
  • 60 Zhang QQ, An X, Liu YH , et al. Long-term nucleos(t)ide analogues therapy for adults with chronic hepatitis B reduces the risk of long-term complications: a meta-analysis. Virol J 2011; 8: 72
    CrossrefPubMedGoogle Scholar
  • 61 Papatheodoridis GV, Manolakopoulos S, Touloumi G , et al; HEPNET. Greece Cohort Study Group. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study. Gut 2011; 60 (8) 1109-1116
    CrossrefPubMedGoogle Scholar
  • 62 Chen CJ, Yang HI, Su J , et al; REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295 (1) 65-73
    CrossrefPubMedGoogle Scholar
  • 63 Chen CF, Lee WC, Yang HI, Chang HC, Jen CL , et al. Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma. Gastroenterology 2011; 141 (4) 1240-1248 , 1248.e1-2
    CrossrefPubMedGoogle Scholar
  • 64 Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50 (3) 661-662
    CrossrefPubMedGoogle Scholar
  • 65 European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57 (1) 167-185
    PubMedGoogle Scholar
  • 66 Mazzella G, Accogli E, Sottili S , et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 1996; 24 (2) 141-147
    CrossrefPubMedGoogle Scholar
  • 67 Benvegnù L, Chemello L, Noventa F, Fattovich G, Pontisso P, Alberti A. Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer 1998; 83 (5) 901-909
    CrossrefPubMedGoogle Scholar
  • 68 Papatheodoridis GV, Dimou E, Dimakopoulos K , et al. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology 2005; 42 (1) 121-129
    CrossrefPubMedGoogle Scholar